Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Synergistic vulnerability of aggressive B-cell lymphoma to combined MCL-1 inhibition and CAR-T cell therapy

Jing Gao, Xiaohong Zhao, Qing Yin, Allen Hu, Kevin Qiu, Loryn Blackburn, Lenny Lei, Rui Xiong, Jeffrey Craig, Craig Portell, Marco Davila, Andy Bi, Michael Williams, Jianguo Tao

Blood (2025) 146 (Supplement 1): 7083.

https://doi.org/10.1182/blood-2025-7083

Published: 2025

Journal Articles

Therapeutic resistance in aggressive B-cell lymphoma is overcome through the reciprocal enhanced efficacy by CDK9 inhibitors and CAR-T cells

Allen Hu, Qing Yin, Michelle Wang, Jing Gao, Kevin Qiu, Loryn Blackburn, Lenny Lei, Rui Xiong, Jeffrey Craig, Craig Portell, Bijal Shah, Michael Williams, Jianguo Tao

Blood (2025) 146 (Supplement 1): 7080.

https://doi.org/10.1182/blood-2025-7080

Published: 2025

Journal Articles

Overcoming therapy resistance with multi-targeted CAR-T cells secreting bispecific antibody (BsAb) for the treatment of B-cell malignancies

Qing Yin, Jing Gao, Xiangao Huang, Allen Hu, Rui Xiong, Loryn Blackburn, Jeffrey Craig, Craig Portell, Selina Chen-Kiang, Michael Williams, Jianguo Tao

Blood (2025) 146 (Supplement 1): 7263.

https://doi.org/10.1182/blood-2025-7263

Published: 2025

Journal Articles

Dysregulation of Transcription Machinery Drives the Acquisition of BTK Inhibitor and Venetoclax Treatment Resistance in Mantle Cell Lymphoma

Jing Gao, Kevin Qiu, Kallesh Danappa Jayappa, Qing Yin, Michelle Wang, Allen Hu, Danielle C Llaneza, Loryn L Blackburn, Jeffrey W Craig, Bijal D Shah, Craig A. Portell, Michael E Williams, Chongzhi Zang, Jianguo Tao

Blood (2024) 144 (Supplement 1): 6220.

https://doi.org/10.1182/blood-2024-204223

Published: 2024

Journal Articles

Combinatorial Therapy of CDK9 Inhibitor with CD19 CAR-T to Reciprocally Overcome Therapy Resistance and Enhance Treatment Efficacies Against Aggressive B-Cell Lymphomas

Qing Yin, Michelle Wang, Allen Hu, Jing Gao, Danielle C Llaneza, Loryn L Blackburn, Jeffrey W Craig, Bijal D Shah, Craig A. Portell, Michael E Williams, Jianguo Tao

Blood (2024) 144 (Supplement 1): 6219.

https://doi.org/10.1182/blood-2024-204209

Published: 2024

Journal Articles

Pharmaocogenomic Characterization of MCL-1 Inhibitor Response and Resistance in Aggressive B-Cell Lymphomas

Michelle Wang, BSE, Tao Li, MD, Yuan Ren, PhD, Bijal Shah, MD, Tint Lwin, MD PhD, Jing Gao, PhD, Kenneth H. Shain, MD PhD, Wei Zhang, PhD, Xiaohong Zhao, MD PhD, Jianguo Tao, MD PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-141407

Published: 2020

Journal Articles

CDK9 As a New Therapeutic Vulnerability for Ibrutinib Resistance Mantle Cell Lymphoma (MCL)

Michelle Wang, BSE, Xiaohong Zhao, MD PhD, Huijuan Jiang, MD, Joy Catherine Yan, Eduardo Sotomayor, MD, Kenneth H. Shain, MD PhD, Bijal Shah, MD, Jianguo Tao, MD PhD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-141386

Published: 2020

Journal Articles

Targeting Kinome Reprogramming for Overcoming Ibrutinib-Resistance (IR) in Mantle Cell Lymphoma (MCL)

Xiaohong Zhao, MD PhD, Huijuan Jiang, MD, Michelle Wang, Tao Li, MD, Jing Gao, PhD, Tint Lwin, MD PhD, Yuan Ren, PhD, Eduardo Sotomayor, MD, Bijal D. Shah, MD, Jianguo Tao, MD PhD

Blood (2018) 132 (Supplement 1): 2651.

https://doi.org/10.1182/blood-2018-99-116756

Published: 2018

Journal Articles

Targeting Oncoprotein Translation with Rocaglates in MYC-Driven Lymphoma

Xuan Zhang, BMBS, Chengfeng Bi, MD PhD, Ting Lu, MD PhD, Ting Yue, Weiwei Zhang, PhD, Xiaoyan Zhang, MD, Wang Cheng, MD, Tian Tian, MD, Matthew A. Lunning, DO, Julie M. Vose, MDMBA, Jerry Pelletier, PhD, John A Porco, Jr., PhD, Jianguo Tao, MD PhD, Kai Fu, MD PhD

Blood (2018) 132 (Supplement 1): 38.

https://doi.org/10.1182/blood-2018-99-117659

Published: 2018

Journal Articles

C-Myc Driven Tolerogenic Tumor Microenvironment (TME) in Mantle Cell Lymphoma (MCL) Is Overcome By Bromodomain Inhibition

Fengdong Cheng, MD, Yuan Ren, PhD, Jie Chen, PhD, Zi Wang, B.S., Tao Li, MD, Kieron Dunleavy, MD, Jianqing Lin, MD, James Bradner, MD, Mitchell R. Smith, MDPhD, Bijal D. Shah, MD, Eduardo Sotomayor, MD, Jianguo Tao, MD PhD

Blood (2018) 132 (Supplement 1): 777.

https://doi.org/10.1182/blood-2018-99-116865

Published: 2018

Journal Articles

Pharmacoproteomics Identifies PLK1 As Vulnerability for Aggressive B-Cell Lymphomas

Blood (2018) 132 (Supplement 1): 2853.

https://doi.org/10.1182/blood-2018-99-118004

Published: 2018

Journal Articles

BRD4: epigenetic origin and target of CTCL

Xiaohong Zhao, Jianguo Tao

Blood (2018) 131 (7): 712–713.

https://doi.org/10.1182/blood-2017-12-820266

Published: 2018

Journal Articles

Venetoclax As a Single Agent and in Combination with PI3K-mTOR1/2 Kinase Inhibitors Against Ibrutinib Sensitive and Resistant Mantle Cell Lymphoma

Huijuan Jiang, MD, Tint Lwin, MD PhD, Bijal D. Shah, MD, Grace T Li, Yuan Ren, Michael W Yan, Lynn C. Moscinski, MD, Xiaohong Zhao, MD PhD, Jianguo Tao, MD PhD

Blood (2017) 130 (Supplement 1): 5197.

https://doi.org/10.1182/blood.V130.Suppl_1.5197.5197

Published: 2017

Journal Articles

JQ1, a Selective Bromodomain Inhibitor, Augment the Immunogenicity of Mantle Cell Lymphoma By Influencing the Expression of PD-L1

Hongwei Wang, MD, Fengdong Cheng, MD, Jie Cheng, PhD, Alejandro Villagra, PhD, Jianguo Tao, MD PhD, James E. Bradner, MD, Eduardo M. Sotomayor, MD

Blood (2015) 126 (23): 822.

https://doi.org/10.1182/blood.V126.23.822.822

Published: 2015

Journal Articles

Polycomb genes, miRNA, and their deregulation in B-cell malignancies

Gang Greg Wang, Kyle D. Konze, Jianguo Tao

Blood (2015) 125 (8): 1217–1225.

https://doi.org/10.1182/blood-2014-10-606822

Published: 2015

Journal Articles

Increased Treatment Intensity Is Not Associated with a Survival Benefit in Patients with Low and Intermediate Risk Mantle Cell Lymphoma, a Retrospective Analysis

Patrick T. Griffin, MD, Julio C Chavez, MD, Celeste M. Bello, MD, Lubomir Sokol, MD PhD, Paul A. Chervenick, MD, Ernesto Ayala, MD, Jianguo Tao, MD PhD, Eduardo M. Sotomayor, MD, Bijal D. Shah, MD

Blood (2014) 124 (21): 4424.

https://doi.org/10.1182/blood.V124.21.4424.4424

Published: 2014

Journal Articles

Selective Inhibition of Histone Deacetylase 6 (HDAC6) and HDAC3 As a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)

Fengdong Cheng, MD, Bing Xia, MD, Eva Sahakian, PhD, Tint Lwin, MD PhD, Hongwei Wang, MD, Limin Xing, MD, Bijal D. Shah, MD, Patricio PerezVillarroel, BS, Maritza LienlafMoreno, BS, Yizhuo Zhang, MD, Steven N Quayle, PhD, Simon S Jones, PhD, Javier Pinilla-Ibarz, MD PhD, Alejandro Villagra, PhD, Eduardo M. Sotomayor, MD, Jianguo Tao, MD PhD

Blood (2014) 124 (21): 5397.

https://doi.org/10.1182/blood.V124.21.5397.5397

Published: 2014

Journal Articles

Seven Year Followup for Bystander Vaccine Therapy in Mantle Cell Lymphoma (MCL)

Bijal D. Shah, MD, Jianguo Tao, MD PhD, Paul A. Chervenick, MD, Marcie L Riches, MD MS, Javier Pinilla-Ibarz, MD PhD, Lynn C. Moscinski, MD, Scott Antonia, MD, Eduardo M. Sotomayor, MD, Sophie Dessureault, MD

Blood (2014) 124 (21): 3083.

https://doi.org/10.1182/blood.V124.21.3083.3083

Published: 2014

Journal Articles

JQ 1, a Selective Bromodomain Inhibitor, Decreased the Expression of the Tolerogenic Molecule PDL1 in Antigen-Presenting Cells (APCs) and Restores the Responsiveness of Anergic CD4+ T Cells

Hongwei Wang, MD, Fengdong Cheng, MD, Limin Xing, MD, Xiaohong Zhao, PhD, Alejandro Villagra, PhD, Javier Pinilla-Ibarz, MD PhD, Jianguo Tao, MD PhD

Blood (2014) 124 (21): 2749.

https://doi.org/10.1182/blood.V124.21.2749.2749

Published: 2014

Journal Articles

Expression of p-STAT5, c-MYC and IKZF1 By Immunohistochemistry May Differentially Correlate with Clinical Outcome in Adult B- Lymphoblastic Leukemia (B-ALL) According to BCR-ABL Status

Bijal D. Shah, MD, Saloomeh Vahdat, MD, Jianguo Tao, MD PhD, Lynn C. Moscinski, MD, Ling Zhang, MD

Blood (2014) 124 (21): 3779.

https://doi.org/10.1182/blood.V124.21.3779.3779

Published: 2014

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Synergistic vulnerability of aggressive B-cell lymphoma to combined MCL-1 inhibition and CAR-T cell therapy

Therapeutic resistance in aggressive B-cell lymphoma is overcome through the reciprocal enhanced efficacy by CDK9 inhibitors and CAR-T cells

Overcoming therapy resistance with multi-targeted CAR-T cells secreting bispecific antibody (BsAb) for the treatment of B-cell malignancies

Dysregulation of Transcription Machinery Drives the Acquisition of BTK Inhibitor and Venetoclax Treatment Resistance in Mantle Cell Lymphoma

Combinatorial Therapy of CDK9 Inhibitor with CD19 CAR-T to Reciprocally Overcome Therapy Resistance and Enhance Treatment Efficacies Against Aggressive B-Cell Lymphomas

Pharmaocogenomic Characterization of MCL-1 Inhibitor Response and Resistance in Aggressive B-Cell Lymphomas

CDK9 As a New Therapeutic Vulnerability for Ibrutinib Resistance Mantle Cell Lymphoma (MCL)

Targeting Kinome Reprogramming for Overcoming Ibrutinib-Resistance (IR) in Mantle Cell Lymphoma (MCL)

Targeting Oncoprotein Translation with Rocaglates in MYC-Driven Lymphoma

C-Myc Driven Tolerogenic Tumor Microenvironment (TME) in Mantle Cell Lymphoma (MCL) Is Overcome By Bromodomain Inhibition

Pharmacoproteomics Identifies PLK1 As Vulnerability for Aggressive B-Cell Lymphomas

BRD4: epigenetic origin and target of CTCL

Venetoclax As a Single Agent and in Combination with PI3K-mTOR1/2 Kinase Inhibitors Against Ibrutinib Sensitive and Resistant Mantle Cell Lymphoma

JQ1, a Selective Bromodomain Inhibitor, Augment the Immunogenicity of Mantle Cell Lymphoma By Influencing the Expression of PD-L1

Polycomb genes, miRNA, and their deregulation in B-cell malignancies

Increased Treatment Intensity Is Not Associated with a Survival Benefit in Patients with Low and Intermediate Risk Mantle Cell Lymphoma, a Retrospective Analysis

Selective Inhibition of Histone Deacetylase 6 (HDAC6) and HDAC3 As a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)

Seven Year Followup for Bystander Vaccine Therapy in Mantle Cell Lymphoma (MCL)

JQ 1, a Selective Bromodomain Inhibitor, Decreased the Expression of the Tolerogenic Molecule PDL1 in Antigen-Presenting Cells (APCs) and Restores the Responsiveness of Anergic CD4+ T Cells

Expression of p-STAT5, c-MYC and IKZF1 By Immunohistochemistry May Differentially Correlate with Clinical Outcome in Adult B- Lymphoblastic Leukemia (B-ALL) According to BCR-ABL Status

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only